[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Aktis Oncology Inc (AKTS)

Aktis Oncology Inc (AKTS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,016,297
  • Shares Outstanding, K 53,405
  • Annual Sales, $ 27,380 K
  • Annual Income, $ -167,950 K
  • EBIT $ 0 M
  • EBITDA $ 0 M
  • 60-Month Beta N/A
  • Price/Sales 152.07
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.40
  • Number of Estimates 6
  • High Estimate $-0.29
  • Low Estimate $-0.53
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.04%

Price Performance

See More
Period Period Low Period High Performance
1-Month
17.88 +6.94%
on 05/11/26
23.05 -17.05%
on 04/24/26
-1.38 (-6.73%)
since 04/21/26
3-Month
14.72 +29.89%
on 03/30/26
23.05 -17.05%
on 04/24/26
+0.22 (+1.16%)
since 02/20/26

Most Recent Stories

More News
Aktis Oncology Reports First-in-Human Clinical Imaging and Dosimetry Data for AKY-2519 Demonstrating Robust Tumor Uptake and Limited Normal Tissue Exposures in Patients with B7-H3 Expressing Tumors

Data to be presented across two posters at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Combined results evaluating AKY-2519 across several B7-H3 expressing tumor types, including...

AKTS : 19.12 (+0.47%)
Aktis: Q1 Earnings Snapshot

Aktis: Q1 Earnings Snapshot

AKTS : 19.12 (+0.47%)
Aktis Oncology Reports Financial Results and Business Highlights for First Quarter 2026

Announced two-trial clinical development strategy for AKY-2519 enabling evaluation in multiple patient segments Initiated Phase 1b clinical trial of AKY-2519 in metastatic castration-resistant prostate...

AKTS : 19.12 (+0.47%)
Aktis Oncology to Present at the BofA Securities Health Care Conference

BOSTON, May 06, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (the “Company”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals...

AKTS : 19.12 (+0.47%)
Aktis Oncology Initiates Phase 1b Clinical Trial for AKY-2519, a B7-H3 Miniprotein Radioconjugate, in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Clinical development strategy includes an mCRPC-dedicated Phase 1b trial in PLUVICTO®-naïve and -experienced patients, and a second Phase 1b basket trial in other B7-H3 expressing solid tumors Two-trial...

AKTS : 19.12 (+0.47%)
Aktis Oncology Announces Presentation of First Clinical Imaging and Dosimetry Data for AKY-2519 at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

AKY-2519, a miniprotein radioconjugate targeting B7-H3, to be featured in two poster presentations Data facilitate initial understanding of AKY-2519 biodistribution and predicted absorbed doses in tumors...

AKTS : 19.12 (+0.47%)
Aktis Oncology Appoints Industry Research and Development Veteran Glenn Gormley, MD, PhD to its Board of Directors

BOSTON, April 16, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (the “Company”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals...

AKTS : 19.12 (+0.47%)
Aktis Oncology Announces FDA Clearance of Investigational New Drug Applications for AKY-2519 and Provides Business Updates and Full Year 2025 Financial Results

Progressing vision to expand the reach of targeted radiopharmaceuticals to large patient populations Anticipating multiple milestones in the next 12 months, including initiation of Phase 1b clinical trial...

AKTS : 19.12 (+0.47%)
Aktis Oncology to Present at Upcoming March Investor Conferences

BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large...

AKTS : 19.12 (+0.47%)
Aktis Oncology Receives U.S. FDA Fast Track Designation for AKY-1189, a Nectin-4 Miniprotein Radioconjugate

U.S. FDA Fast Track designation granted to AKY-1189 1 for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have progressed on or after prior systemic therapies...

AKTS : 19.12 (+0.47%)

Business Summary

Aktis Oncology Inc. is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. Aktis Oncology Inc. is based in BOSTON.

See More

Key Turning Points

3rd Resistance Point 20.30
2nd Resistance Point 19.76
1st Resistance Point 19.44
Last Price 19.12
1st Support Level 18.58
2nd Support Level 18.04
3rd Support Level 17.72

See More

52-Week High 29.16
Fibonacci 61.8% 23.64
Fibonacci 50% 21.94
Fibonacci 38.2% 20.24
Last Price 19.12
52-Week Low 14.72

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.